Prospective comparative study of dose dense neo-adjuvant chemotherapy followed by chemo-radiation and definitive chemo-radiation alone in stage IB2-IVA cervical cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20162844Keywords:
Neo-adjuvant chemotherapy, Cancer cervix, Dose denseAbstract
Background: The standard of care for locally advanced cervical cancer is chemo-radiation. Role of neo-adjuvant chemotherapy not clear yet. Dose dense, short-term neo-adjuvant chemotherapy with early initiation of radiotherapy has shown survival benefit but randomised trials not available yet. Hence this study was done for feasibility of neo-adjuvant chemotherapy and for its comparison with the standard chemo-radiation.
Methods: Cervical cancer patients not randomly assigned into two arms. Arm A received 3 cycles NACT of paclitaxel and carboplatin weekly. All patients of arm A after NACT and arm B received EBRT on linear accelerator for a dose of 4500-5000cGy in 23-25 fractions with concurrent cisplatin 40mg/m2 followed by 3 applications of HDR intracavitary brachytherapy of 700 or 800cGy respectively. All patients were assessed clinically and radiologically with MRI after completion of CTRT and at follow up of 6 weeks.
Results: A total of 15 patients treated in each arm. Stage IIB and IIIB constituted 93% of the patients, well matched in both the arms. The CR rate at follow up of 6 weeks after NACT was 73% compared to only 46.7% in arm B. Neutropenia of grade 3 were seen equally in both the arms and grade 2 neutropenia was seen in about 60% patients in arm A compared to only 20% patients in arm B which was manageable without growth factors.
Conclusions: Dose dense neo-adjuvant chemotherapy is a feasible and effective option in treating cancer cervix.References
Lindsey AT, Freddie B, Rebecca LS, Jacques F, Joannie LT, Ahmedin J. Global cancer statistics. 2012, Cancer J Clin. 2015;65:87-108.
Eifel PJ, Berek JS, Thigpen JT. Gynecologic Cancers. Section 2. Cancer of the cervix, vagina, vulva. In: DeVita VT Jr, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. Sixth Edition, Philadelphia: Lippincott-Raven, 2001:1526-1556.
Claire V. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomised trials. J Clin Oncol. 2008;26(35):5802-12.
Tierney J. Neoadjuvant chemotherapy for cervical cancer meta-analysis collaboration (NACCCMA) collaboration. ‘Neoadjuvant chemotherapy for locally advanced cervix cancer’. Cochrane Database Syst Rev. 2004:14651858.
Bernard R. Fundamentals of Biostatistics, 5th Edition, Duxbury,2000:80-240.
Robert HR. Statistics in Medicine, second edition, Academic press. 2005;85-125.
Rao S, Richard J. An introduction to biostatistics, A manual for students in health sciences, 4th edition New Delhi: India. 2006:86-160.
Suresh KP, Chandrasekhar S. Sample Size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5:7-13.
Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, et al. Long- term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol. 1997;67:61-9.
Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 2004;92:59-63.
Cormack M, Ledermann JA, Hall CMA, Symonds RP. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. J Clin Oncol. 2009;27:15.
Park DC, Suh MJ, Yeo SG. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results. Int J Gynecol Cancer. 2009;19:943-7.
Mori T, Hosokawa K, Kinoshita Y, Watanabe A, Honjo H. Neo-adjuvant chemotherapy with weekly carboplatin and paclitaxel for carcinoma cervix. Int J Gynecol Cancer. 2008;18:85-9.
